molecules of the month

“Compound 20”

cryo-EM-characterized TRPA1 ion channel inh.

oral efficacy (10 mpk BID) in asthma model

rational design from literature starting point

J. Med. Chem., Mar. 22, 2021

Genentech, South San Francisco, CA

Structure of compound 20
1 min read

The Genentech transient receptor potential ankyrin 1 (TRPA1) inhibitor (“compound 20”) is an ion channel inhibitor with a binding site and mechanism of action characterized by cryo-EM. Structural information for ion-channel targets is rare as X-ray co-crystal structures of membrane-bound proteins are difficult to obtain. The article is an interesting case study for using conformational analysis to improve drug molecules, and the authors highlight several interesting attempted linker rigidification strategies. Compound 20 is orally efficacious in a guinea pig asthma model demonstrating a substantial reduction in inflammatory response due to BALF infiltrates in the airways around 10 mg/kg BID.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: